You just read:

Jazz Pharmaceuticals Announces FDA Approval of Xyrem® (sodium oxybate) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients

News provided by

Jazz Pharmaceuticals plc

29 Oct, 2018, 12:00 GMT